New R&D Tax Incentives Enough To Support Korean Drug Development?
This article was originally published in PharmAsia News
The South Korean government has unveiled more details of new R&D tax support for emerging industries, including bio-health care, to encourage research spending by the pharma sector. But a local industry association suggests the government may also have to think twice about an existing R&D tax incentive system that provides incremental reductions and gives preferential benefits to smaller firms.
You may also be interested in...
South Korea unveils its first comprehensive plan for the overall development of the health care industry, with a focus on developing novel therapies for rare and incurable diseases, precision and regenerative medicine, and customized health management systems, with the aims of improving care, controlling costs, and raising global industry competitiveness.
US FDA defers action on Spectrum’s approval application for neutropenia candidate Rolontis due to pandemic-related difficulties inspecting partner Hanmi’s plant. The action date has been put back by around four months although the companies stress no CRL has been issued.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.